For instance, regarding gastrointestinal and cutaneous adverse events, the MOUNTAINEER trial[7] found that tucatinib combined with trastuzumab in treating HER2+ metastatic colorectal cancer most frequently induced diarrhea, fatigue, rash, and nausea. Here, ERBB2 is linked to metastatic colorectal cancer.